Global Pulmonary Drug Delivery Systems Market Report and Forecast 2024-2032

Global Pulmonary Drug Delivery Systems Market Outlook

The global pulmonary drug delivery systems market size was valued at USD 56.9 billion in 2023, driven by the increasing incidence of respiratory conditions across the globe. The market size is anticipated to grow at a CAGR of 5.65% during the forecast period of 2024-2032 to achieve a value of USD 93.3 billion by 2032.

Pulmonary Drug Delivery Systems: Introduction

Pulmonary drug delivery systems are medical devices or drug formulations designed to deliver medications directly to the lungs through inhalation. These systems are used to treat various respiratory conditions, such as asthma, chronic obstructive pulmonary disease (COPD), cystic fibrosis, and respiratory infections, among others. Pulmonary drug delivery offers several advantages, including rapid onset of action, targeted drug delivery to the lungs, and reduced systemic side effects compared to oral or intravenous administration.

Global Pulmonary Drug Delivery Systems Market Analysis

The growth of the market is driven by the strategic collaborations between pharma giants to resolve issues together resulting in increased market growth. For example, the strategic partnership between Hovione and H&T Presspart to develop the Sunriser© Capsule-based DPI platform is expected to address the evolving requirements of the pulmonary drug delivery systems market as they offer more efficient and adaptable solutions for inhalable medications. The development of the Sunriser© DPI is expected to result in more efficient and effective delivery of inhalable drugs resulting in enhanced patient compliance and outcomes for various respiratory conditions, such as asthma and chronic obstructive pulmonary disease (COPD).

The market growth is also driven by increased innovation, coupled with expanded product offerings, and improved drug delivery options for patients. Such collaborations are expected to influence the market greatly as they may result in patient-friendly, efficient, and adaptable inhalation solutions propelling the global pulmonary drug delivery systems market growth.

Global Pulmonary Drug Delivery Systems Market Segmentations

Market Breakup by Product Type

• Dry Powder Inhalers 

• Metered Dose Inhalers 

• Nebulizers
  • Jet Nebulizers 
  • Soft Mist Nebulizers 
  • Ultrasonic Nebulizers 

• Others

Market Breakup by Applications

• Cystic Fibrosis

• Asthma

• Allergic Rhinitis

• COPD

• Others

Market by End User

• Hospitals

• Diagnostic Centres

• Homecare Settings

• Others

Market Breakup by Region

• North America

• Europe

• Asia Pacific

• Latin America

• Middle East and Africa

Global Pulmonary Drug Delivery Systems Market Overview

The global market for pulmonary drug delivery systems is experiencing significant growth driven by the increasing prevalence of respiratory diseases such as asthma, chronic obstructive pulmonary disease (COPD), and cystic fibrosis. With these conditions continuing to affect a substantial portion of the global population, there is a growing demand for effective drug delivery systems specifically designed for pulmonary treatments in the market.

Additionally, advancements in inhalation technologies and drug formulations are also enhancing the efficiency and effectiveness of pulmonary drug delivery, further propelling the pulmonary drug delivery systems market growth.

Furthermore, the COVID-19 pandemic has highlighted the importance of respiratory health, leading to increased awareness and investments in pulmonary drug delivery systems. The need for efficient administration of respiratory medications, including vaccines and therapies for various lung infections is expected to further drive innovation and development of novel delivery devices in the market, propelling the market growth.

The increasing geriatric population, particularly in developed countries, is contributing to increased respiratory-related illnesses, further aiding the pulmonary drug delivery systems market demand. As healthcare systems focus on patient-centric care and improved treatment outcomes, the market is witnessing a surge in research and development activities, new product launches, and strategic collaborations. All these factors collectively are boosting the global market and are expected to drive the market in coming years as well.

Global Pulmonary Drug Delivery Systems Market: Competitor Landscape

The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:

• Koninklijke Philips NV

• GlaxoSmithKline PLC

• 3M

• Novartis AG

• Boehringer Ingelheim International GmbH

• AstraZeneca

• Cipla Inc.

• Merck & Co.

• GF Health Products Inc.

• Aerogen

• PARI GmbH

• Gilbert Technologies

Key Highlights of the Report